Meeting
2022 ASCO Gastrointestinal Cancers Symposium
The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.
Authors
Maliha Nusrat
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Maliha Nusrat , Muddassir Ali Syed , Riham Katkhuda , Edwin R. Parra , Ignacio Ivan Wistuba , Paul Kong , Amanda Koehne , Arvind Dasari , Michael J. Overman , David Menter , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
DOI
10.1200/JCO.2022.40.4_suppl.154
Abstract #
154
Poster Bd #
H5
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2016 ASCO Annual Meeting
Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC.
First Author: Matthew Reilley
First Author: Susanna Swoboda
Poster
2023 ASCO Genitourinary Cancers Symposium
Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study).
First Author: Laura Cattaneo